

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A water-in-oil microemulsion comprising a retinoid as active ingredient, a phospholipid emulsifier, and sodium hyaluronate, wherein:

the aqueous phase is present at a concentration ranging from 0.5 to 2% by weight;

the phospholipid emulsifier is phosphatidylcholine or soy lecithin, and is present in an amount ranging from 10 to 15% by weight;

the sodium hyaluronate is a fraction having a molecular weight ranging from 50 to 200 kDa, and is present in an amount ranging from 0.001 to 0.01% by weight; and

the molar ratio of molar water concentration to molar lecithin phospholipid emulsifier concentration (W/lec) (W/PE) is 3.

2. (cancelled)

3. (currently amended) The microemulsion of claim 1, wherein the oil phase consists of alkyl esters of C₁₀-C₂₂ fatty acids.

4. (previously presented) The microemulsion of claim 3, wherein the oil phase consists of isopropyl palmitate.

5. (previously presented) The microemulsion of claim 1, wherein the retinoid is selected from the group consisting of isotretinoin (13-cis-retinoic acid), tazarotene and fenretinide.

6. (previously presented) The microemulsion of claim 5, wherein the retinoid is fenretinide.

7. (cancelled)

8. (currently amended) The microemulsion of claim 1, further comprising at least one derivative of hyaluronic acid (HA) selected from the group consisting of:

HA salts with organic inorganic bases with a molecular weight of 50-730 KDa or a high molecular weight of 750-1230 KDa;

esters of HA with alcohols of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;

amides of HA with amines of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;

O-sulphated HA derivatives up to the 4th degree of sulphation; and

~~inner esters of auto-crosslinked HA.~~

9. (currently amended) The microemulsion of claim 1, further comprising antioxidants and preservatives.

10. (currently amended) The microemulsion of claim 9, containing ~~α-tocopherol~~ α-tocopherol and parabens.

11. (previously presented) A pharmaceutical composition comprising the microemulsions of claim 1.

12. (previously presented) A method of preparing medicinal products with chemoprotective activity, which comprises adding an effective amount of the microemulsion according to claim 1 to an acceptable carrier.

13. (currently amended) A method for preparing the microemulsion of claim 1, which comprises the addition of a solution of phospholipid emulsifier in the oil phase to a retinoid solution in the same oil phase, ~~or~~ and the subsequent addition of an aqueous solution.

14. (previously presented) The microemulsion of claim 1, wherein the weight percentage of active ingredients is from 0.01% to 0.5% in weight.

15. (previously presented) The microemulsion of claim 1, wherein the sodium hyaluronate promotes percutaneous absorption of the water-in-oil microemulsion.

16. (previously presented) The microemulsion of claim 1, wherein the fraction of sodium hyaluronate having a molecular weight ranging from 50 to 200 kDa is hyalastine.

17. (currently amended) The method of claim 13, wherein the aqueous solution comprises hyaluronic acid (HA), HA salts or HA derivatives thereof, preservatives, or EDTA, and the HA derivative is selected from the group consisting of:

HA salts with organic inorganic bases with a molecular weight of 50-730 KDa or a high molecular weight of 750-1230 KDa;
esters of HA with alcohols of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;
amides of HA with amines of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;
O-sulphated HA derivatives up to the 4th degree of sulphation; and
auto-crosslinked HA.